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ABSTRACT
NVP PDF-713 (LBM 415) is a peptide deformylase
inhibitor being progressed into clinical trials. Dry-
form broth microdilution panels of NVP PDF-713
were compared to reference MIC panels of 552
recent clinical isolates. Most (99.2%) dry-form
MIC results were within ± 1 log2 dilution of the
reference panel MICs. Of the bacteria tested,
Streptococcus pneumoniae and Haemophilus influen-
zae showed a bias towards higher and lower
MICs, respectively. Same-day and between-day
reproducibility tests showed that 98.9% and
96.7% of MIC values, respectively, were within
± 1 log2 dilution step, thereby demonstrating a
high degree of reliability of the dry-form MIC
product for clinical studies.
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NVP PDF-713 (LBM 415) (Novartis Pharmaceuti-
cals, Basel, Switzerland) is one of the first inhib-
itors of the bacterial enzyme peptide deformylase
(PDF) to be progressed into human clinical trials
for the oral or parenteral treatment of community-
acquired respiratory tract infections and serious
infections caused by susceptible Gram-positive
pathogens. PDF is required in bacteria for protein
maturation, but is not found in eukaryotic cells,
making it an attractive target with a new mech-
anism of action for inhibition by antibacterial
agents [1,2]. In addition to documented activity
against major respiratory tract pathogens, inclu-
ding Streptococcus pneumoniae, Haemophilus influ-
enzae, Moraxella catarrhalis, Chlamydia pneumoniae
and Staphylococcus aureus, NVP PDF-713 has
appropriate oral bioavailability, pharmacokinetic
parameters and safety, making it an excellent
candidate for further clinical study and develop-
ment. PDF inhibitors are less active generally
against most Gram-negative species, with the
exception of anaerobes and the species mentioned
above [3,4]. NVP PDF-713 retains activity against
penicillin-resistant Strep. pneumoniae, methicillin-
resistant S. aureus and vancomycin-resistant en-
terococci. Fortuitously, cross-resistance with other
classes of antimicrobials has not been detected [5].
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Laboratory support for continued development
of this compound in clinical trials will require
accurate and reproducible susceptibility testing
products for use by collaborating investigators.
Appropriate MIC quality control (QC) ranges
have been established according to National
Committee for Clinical Laboratory Standards
(NCCLS) guidelines [6] as part of a multicentre
study [7] in which eight laboratories tested four
QC strains daily for 10 days with reference
methods [8]. QC ranges for reference methods
having been established, commercially available
MIC products that are comparable to the
reference method, but which have an extended
shelf-life, must be made available for routine
susceptibility testing. This report summarises the
results of tests to determine the equivalent per-
formance and reproducibility of commercial dry-
form MIC panels when compared to the reference
broth microdilution method [8].
Minimal criteria for the number of organisms
tested [7] were achieved by processing 66 S. aureus
isolates, 42 coagulase-negative staphylococcus iso-
lates, 100 Strep. pneumoniae isolates, 52 b-haemo-
lytic streptococcus isolates, 48 viridans group
streptococcus isolates, 101 Enterococcus spp. iso-
lates and 100 H. influenzae isolates. In addition, 42
strains of various Gram-negative bacilli (26
Enterobacteriaceae, ten Pseudomonas aeruginosa,
six other non-fermentative bacilli) expected to
produce off-scale (resistant) MIC results were
tested.
The broth microdilution trays were produced
by TREK Diagnostics ⁄ Sensititre (Cleveland, OH,
USA) as dry-form panels containing an amorphous
preparation of NVP PDF-713 (dilution range,
0.06–8 mg ⁄L) in a final post-inoculum volume of
0.1 mL. Reference trays used for comparison were
prepared in the same volume of cation-adjusted
Mueller–Hinton broth (Difco, Detroit, MI, USA),
and frozen at £) 70C until used [8]. In addition
to comparator antimicrobial agents and the amor-
phous preparation of the PDF inhibitor, the
reference panels contained the Mg2+ salt (crystal-
line) form of NVP PDF-713. The same inoculum
(5 · 105 CFU ⁄mL) was used for testing, with
endpoints conforming to NCCLS criteria being
interpreted at organism-specific times ranging
from 18 to 24 h [8]. QC organisms recommended
by the NCCLS [8] were included in the total
(Strep. pneumoniae ATCC 49619, H. influenzae
ATCC 49247). All recorded QC results for NVP
PDF-713 and vancomycin (control agent) were
within the published limits [6,9].
The reproducibility phase of the study consis-
ted of tests on ten strains of Gram-positive cocci
three-times-daily for 3 days, yielding a total of 90
determinations. Four were QC strains (Strep.
pneumoniae ATCC 49619, E. faecalis ATCC 29212,
and S. aureus ATCC 29213 and 25923). Target
values for inter-method accuracy were defined as
‡ 95% of results within ± 1 log2 dilution of the
reference test result, with ‡ 50% yielding the same
MIC value. Acceptable reproducibility was
defined as ‡ 95% of results within ± 1 log2 dilu-
tion step of the overall modal MIC, analysed on
the same day and between days of testing.
Table 1 summarises the results of the validation
study comparing NCCLS frozen-form reagent
panels [8] of NVP PDF-713 with commercial dry-
form panels. For organisms within the spectrum of
activity of this compound, 54% of MIC values
Table 1. Validation experiments
comparing the results from dry-form
NVP PDF-713 broth microdilution
trays with reference frozen-form
NVP PDF-713 tray MICs
Organisms collected (no. tested)
Dry-form MIC variations (log2 dilutions)
- 2 - 1 Same + 1 + 2 + 3
Within the spectrum of the compound
Staphylococcus spp. (108) 0 19 76 13 0 0
Enterococcus spp. (101) 0 33 55 13 0 0
Streptococcus pneumoniae (100) 0 7 35 54 3 1
Other Streptococcus spp. (100) 0 22 70 8 0 0
Haemophilus influenzae (100) 0 61 38 1 0 0
Subtotal (509) 0 142 274 89 3 1
Percentage 0 27.9 53.8 17.5 0.6 0.2
Other Gram-negative bacillia (42) 0 1 40 1 0 0
All strains (551) 0 143 314 90 3 1
Percentage 0 26.0b 57.0b 16.3b 0.5 0.2
aIncludes Enterobacteriaceae (26 strains), Pseudomonas aeruginosa (ten strains) and non-fermentative bacilli (six
strains); 39 of 42 tests yielded MICs > 32 mg ⁄L.
b99.3% of all NVP PDF-713 results, and 99.2% of all results for those organisms falling within the spectrum of
activity, were within ± 1 log2 dilution; 57.0% had the same MIC value by both tested methods, meeting target
objectives for validation (‡ 50%).
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obtained by the two methods were identical
(ranging from 35% for Strep. pneumoniae to 70%
for staphylococci and streptococci other than Strep.
pneumoniae), and 99.2% were within ± 1 log2 dilu-
tion of the reference test result. Consistent varia-
tions were detected only with Strep. pneumoniae
(58% of dry-form panel MIC results being two-fold
greater or more above the reference panel) and
H. influenzae (61% of MIC results being 1 log2
dilution lower than the reference panel).
While isolates were selected to minimise off-
scale results, five viridans group streptococci
(< 1% of the total) gave off-scale (£ 0.06 mg ⁄L)
results. For the purposes of this analysis, a result
of £ 0.06 mg ⁄L was considered equivalent to
0.06 mg ⁄L. MICs were off-scale (> 32 mg ⁄L) for
all Enterobacteriaceae and for 13 of 16 non-
fermentative Gram-negative bacilli (40 strains in
total); for analysis purposes, these results were
considered identical (no variation). Interestingly,
all three strains of Stenotrophomonas maltophilia
tested had on-scale results with MICs of 2, 4 and
16 mg ⁄L. The activity of NVP PDF-713 against
this particular species warrants further investiga-
tion. For all organisms (n = 551) tested, 57.0% of
results were identical, and 99.3% of results were
within ± 1 log2 dilution.
A comparison of MIC results for the two formu-
lations of NVP PDF-713 (crystalline and amor-
phous) was performed with the frozen reference
panels for all organisms tested. Most (96%) crystal-
line MICs were identical to those obtained with
the amorphous formulation, and all comparisons
were within ± 1 log2 dilution step (data not shown).
The Mg2+ salt formulation, in addition to demon-
strating equivalent performance, has the added
properties of enhanced solubility and a greater
stability profile, which are important considerations
in the development of broth microdilution panels.
The reproducibilities of same-day and between-
day exact reproducibility tests were 84.4% and
75.6%, respectively (Table 2), with 98.9% and
96.7% of MIC values, respectively, being within
± 1 log2 dilution step. All MIC results were on-scale
(0.25–4 mg ⁄L). These results exceeded the prede-
fined criteria established for acceptable perform-
ance [7].
In conclusion, this study examined the ability of
commercial broth microdilution dry-form panels
of NVP PDF-713 (LBM 415) to produce accurate
MIC results in comparison with an established
reference method [8]. The accuracy and repro-
ducibility of the dry-form panels were observed
to be within acceptable limits [7]. The commercial
dry-form product can be used to produce accurate
and reproducible results in support of further
clinical trials, when used according to the manu-
facturer’s directions and when controlled by
using appropriate organisms and methods as
found in published guidelines [8,9].
Table 2. Results obtained with dry-
form commercial NVP PDF-713 MIC
panels with three replicates daily for
three separate days (90 total results)a
Organisms
NVP PDF-713 MIC variation (log2 dilutions)
Replicates on same dayb Replicates between daysc
- 2 - 1 Same + 1 + 2 - 2 - 1 Same + 1 + 2
Enterococcus faecalis
ATCC 29212
0 0 7 2 0 0 0 7 2 0
Enterococcus faecalis
95-16130
0 0 9 0 0 0 0 9 0 0
Enterococcus faecium
102-15947A
0 1 8 0 0 0 1 8 0 0
Streptococcus pneumoniae
ATCC 49619
0 1 8 0 0 0 1 8 0 0
Streptococcus pneumoniae
102-16000A
1 1 6 1 0 0 2 4 3 0
Streptococcus pyogenes
7-16229A
0 1 8 0 0 0 1 8 0 0
Staphylococcus aureus
ATCC 25923
0 0 7 2 0 0 4 5 0 0
Staphylococcus aureus
ATCC 29213
0 0 8 1 0 0 0 8 1 0
Staphylococcus epidermidis
102-15955
0 2 7 0 0 0 2 7 0 0
Staphylococcus epidermidis
96-16267
0 0 8 1 0 3 2 4 0 0
Total 1 6 76 7 0 3 13 68 6 0
Percentage 1.1 6.7 84.4b 7.8 0 3.3 14.4 75.6c 6.7 0
aAll MIC results were on-scale values (0.25–4 mg ⁄L).
bExact replicate-to-replicate reproducibility was 84.4%. Nearly all MIC results (98.9%) were ± 1 log2 dilution step.
cThe exact MIC was achieved between days for 75.6% of tests. Almost all (96.7%) were ± 1 log2 dilution step.
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